Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2

Conditions: Male Breast Cancer
Stage II Breast Cancer
Estrogen Receptor-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage IA Breast Cancer
Stage IIIC Breast Cancer
Triple-negative Breast Cancer
HER2-negative Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: eribulin mesylate
Drug: carboplatin
Procedure: biopsy

First Posted Date: 2011-06-14

Last Posted Date: 2019-06-07

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT01372579

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Not Applicable

Terminated

Conditions: Uterine Carcinosarcoma
Stage IB Uterine Sarcoma
Stage IC Uterine Sarcoma
Stage IIB Uterine Sarcoma
Stage IVA Uterine Sarcoma
Stage IVB Uterine Sarcoma
Stage IA Uterine Sarcoma
Stage IIA Uterine Sarcoma
Stage IIIC Uterine Sarcoma
Stage IIIA Uterine Sarcoma

Interventions: Drug: paclitaxel
Drug: carboplatin
Radiation: external beam radiation therapy
Radiation: brachytherapy
Radiation: intensity-modulated radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2011-06-07

Last Posted Date: 2023-08-21

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 14

Registration Number: NCT01367301

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: MEGF0444A
Drug: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Drug: placebo

First Posted Date: 2011-06-03

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 104

Registration Number: NCT01366131

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Stage I Ovarian Cancer AJCC v6 and v7
Stage IA Fallopian Tube Cancer AJCC v6 and v7
Stage IC Fallopian Tube Cancer AJCC v6 and v7
Stage IB Fallopian Tube Cancer AJCC v6 and v7
Stage IIIC Fallopian Tube Cancer AJCC v7
Stage IIB Fallopian Tube Cancer AJCC v6 and v7
Stage III Primary Peritoneal Cancer AJCC v7
Stage IIIA Fallopian Tube Cancer AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7
Stage IIA Fallopian Tube Cancer AJCC v6 and v7

Interventions: Procedure: Assessment of Therapy Complications
Drug: Carboplatin
Biological: Filgrastim
Drug: Paclitaxel
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2011-06-03

Last Posted Date: 2021-09-30

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 290

Registration Number: NCT01366183

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States

and more 351 locations

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1

Active, not recruiting

Conditions: Ovarian Carcinoma
Unresectable Malignant Neoplasm
Endometrial Carcinoma
Melanoma
Breast Carcinoma
Malignant Head and Neck Neoplasm
Malignant Testicular Neoplasm
Metastatic Malignant Solid Neoplasm
Renal Failure
Esophageal Carcinoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2011-06-03

Last Posted Date: 2024-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT01366144

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 14 locations

A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2011-06-02

Last Posted Date: 2018-02-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 276

Registration Number: NCT01364012

Locations: 🇨🇳
Beijing Hospital of Ministry of Health; Hematology, Beijing, China
🇨🇳
General Hospital of Chinese PLA; Department of Hematology, Beijing, China
🇨🇳
Beijing Chest Hospital; Oncology Department, Beijing, China

and more 14 locations

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Doxorubicin
Drug: Epirubicin
Drug: Paclitaxel
Drug: Placebo
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2011-05-24

Last Posted Date: 2024-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4804

Registration Number: NCT01358877

Locations: 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 552 locations

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: adavosertib
Drug: Placebo
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2011-05-20

Last Posted Date: 2023-09-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 136

Registration Number: NCT01357161

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1

Completed

Conditions: Urethral Neoplasms
Neoplasms, Urethral
Cancer of the Urethra
Urethral Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Lenalidomide

First Posted Date: 2011-05-12

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01352962

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Not Applicable

Active, not recruiting

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Radiation: hypofractionated radiation therapy
Other: laboratory biomarker analysis
Radiation: image-guided radiation therapy
Drug: carboplatin
Drug: paclitaxel
Radiation: stereotactic body radiation therapy

First Posted Date: 2011-05-02

Last Posted Date: 2024-01-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 29

Registration Number: NCT01345851

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy